Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285065508> ?p ?o ?g. }
- W4285065508 endingPage "175883592211065" @default.
- W4285065508 startingPage "175883592211065" @default.
- W4285065508 abstract "Although human epidermal growth factor receptor 2 (HER2)-positive breast cancer was associated with poor prognosis, it has been changed after the development of trastuzumab. There has been great progress in perioperative HER2-targeting treatment, and investigations of several novel drugs and their combinations are ongoing. Adjuvant trastuzumab with or without pertuzumab for 1 year in combination with concomitant chemotherapy has become a standard treatment in high-risk node-negative tumors or node-positive HER2-positive early breast cancer patients without residual disease or who have not received neoadjuvant treatment. For low-risk HER2-positive early breast cancer patients, adjuvant paclitaxel and 1-year trastuzumab are possible alternatives. For residual disease after neoadjuvant treatment, adjuvant trastuzumab emtansine (T-DM1) for 14 cycles is a standard treatment. Non-anthracycline chemotherapy with dual anti-HER2 targeting of trastuzumab and pertuzumab represents one of the preferred neoadjuvant regimens to achieve higher pathologic complete response (pCR) rates and better clinical outcomes. Further research is needed to develop and validate potential biomarkers to predict pCR, which could help escalate or de-escalate anti-HER2 therapy. Trials incorporating novel agents such as T-DM1, trastuzumab deruxtecan (T-DXd), and immune checkpoint inhibitors and trying to de-escalate treatments in neoadjuvant setting are ongoing. In the future, tailored treatments such as no adjuvant therapy, various HER2-directed therapies alone with chemotherapy, combinations of various HER2-directed therapies and chemotherapy, addition of immune checkpoint inhibitors, and omission of surgery will be individualized in HER2-positive early breast cancer patients." @default.
- W4285065508 created "2022-07-13" @default.
- W4285065508 creator A5007089296 @default.
- W4285065508 creator A5038858741 @default.
- W4285065508 date "2022-01-01" @default.
- W4285065508 modified "2023-10-14" @default.
- W4285065508 title "Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer" @default.
- W4285065508 cites W1964808503 @default.
- W4285065508 cites W1987326983 @default.
- W4285065508 cites W1991697331 @default.
- W4285065508 cites W1993804787 @default.
- W4285065508 cites W1996778928 @default.
- W4285065508 cites W2040935952 @default.
- W4285065508 cites W2053074390 @default.
- W4285065508 cites W2075894019 @default.
- W4285065508 cites W2080550759 @default.
- W4285065508 cites W2086965131 @default.
- W4285065508 cites W2095633632 @default.
- W4285065508 cites W2095861620 @default.
- W4285065508 cites W2095865154 @default.
- W4285065508 cites W2096818458 @default.
- W4285065508 cites W2098775844 @default.
- W4285065508 cites W2110444464 @default.
- W4285065508 cites W2111578514 @default.
- W4285065508 cites W2113450161 @default.
- W4285065508 cites W2115759102 @default.
- W4285065508 cites W2120627364 @default.
- W4285065508 cites W2123591186 @default.
- W4285065508 cites W2125239609 @default.
- W4285065508 cites W2128458647 @default.
- W4285065508 cites W2135753253 @default.
- W4285065508 cites W2137228442 @default.
- W4285065508 cites W2141393790 @default.
- W4285065508 cites W2144124503 @default.
- W4285065508 cites W2146384083 @default.
- W4285065508 cites W2147415463 @default.
- W4285065508 cites W2149908785 @default.
- W4285065508 cites W2150086065 @default.
- W4285065508 cites W2151262170 @default.
- W4285065508 cites W2152121934 @default.
- W4285065508 cites W2154246971 @default.
- W4285065508 cites W2159967578 @default.
- W4285065508 cites W2162488896 @default.
- W4285065508 cites W2166199281 @default.
- W4285065508 cites W2170181527 @default.
- W4285065508 cites W2171277704 @default.
- W4285065508 cites W2175026167 @default.
- W4285065508 cites W2242881904 @default.
- W4285065508 cites W2264000214 @default.
- W4285065508 cites W2283816551 @default.
- W4285065508 cites W2318605753 @default.
- W4285065508 cites W2352525452 @default.
- W4285065508 cites W2379981061 @default.
- W4285065508 cites W2387397851 @default.
- W4285065508 cites W2399215084 @default.
- W4285065508 cites W2497521261 @default.
- W4285065508 cites W2499208470 @default.
- W4285065508 cites W2556950207 @default.
- W4285065508 cites W2588881638 @default.
- W4285065508 cites W2611671407 @default.
- W4285065508 cites W2616596696 @default.
- W4285065508 cites W2624590002 @default.
- W4285065508 cites W2626331869 @default.
- W4285065508 cites W2768649895 @default.
- W4285065508 cites W2768980003 @default.
- W4285065508 cites W2774227900 @default.
- W4285065508 cites W2791139688 @default.
- W4285065508 cites W2795193052 @default.
- W4285065508 cites W2806629158 @default.
- W4285065508 cites W2806866264 @default.
- W4285065508 cites W2889673459 @default.
- W4285065508 cites W2899659781 @default.
- W4285065508 cites W2902218997 @default.
- W4285065508 cites W2903044532 @default.
- W4285065508 cites W2908170962 @default.
- W4285065508 cites W2928807055 @default.
- W4285065508 cites W2942862617 @default.
- W4285065508 cites W2946850537 @default.
- W4285065508 cites W2948405934 @default.
- W4285065508 cites W2948720210 @default.
- W4285065508 cites W2948726637 @default.
- W4285065508 cites W2965526302 @default.
- W4285065508 cites W2972654722 @default.
- W4285065508 cites W2980831576 @default.
- W4285065508 cites W2996630100 @default.
- W4285065508 cites W2998950563 @default.
- W4285065508 cites W3027252353 @default.
- W4285065508 cites W3027663151 @default.
- W4285065508 cites W3028719789 @default.
- W4285065508 cites W3092280067 @default.
- W4285065508 cites W3093646952 @default.
- W4285065508 cites W3109164129 @default.
- W4285065508 cites W3126817559 @default.
- W4285065508 cites W3138322242 @default.
- W4285065508 cites W3157823694 @default.
- W4285065508 cites W3158285997 @default.
- W4285065508 cites W3160666703 @default.
- W4285065508 cites W3161369373 @default.